KEY FINDINGS
The Europe infertility testing & treatment market is forecasted to grow with a CAGR of 10.73% over the estimated period of 2021 to 2028. The high awareness associated with infertility, the presence of advanced healthcare facilities, and the increasing age of conception and late marriages are among the key factors accredited to the regional market’s growth.
MARKET INSIGHTS
The Europe infertility testing & treatment market growth assessment includes the evaluation of Russia, Poland, Italy, France, the United Kingdom, Germany, Belgium, and the rest of Europe. As per the ‘Alarming Public Health Report on Infertility in France,’ published in 2018, exposure to toxic substances and environmental factors were considered the leading causes of infertility in men. The study found that sperm concentration plummeted by 1.9% annually, indicating a decline of more than 32% over the last 15 years. Moreover, the number of morphologically normal spermatozoids is decreasing in France, as well.
In Italy, obesity has been cited as a serious health issue over the years. According to the data issued by the Organization for Economic Co-operation and Development (OECD), nearly 1 in 10 people in the country are obese. However, this number is considerably lesser than the OECD average of 1 in 6 people. The estimations also indicate that the rate of being overweight is likely to increase by an additional 5% over the next decade. As a result, with the rise in obesity rates, the number of fertility cases also continue to grow. Thus, these factors are set to propel the Europe infertility testing & treatment market.
COMPETITIVE INSIGHTS
Some of the top companies operating in the market are Endo International PLC, Halotech DNA, Vitrolife AB, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING STRESS AND LIFESTYLE DISORDERS
3.1.2. INCREASED AGE OF CONCEPTION
3.1.3. INCREASING EFFECTIVENESS OF TREATMENTS
3.1.4. RISING GOVERNMENT SUPPORT
3.2. KEY RESTRAINTS
3.2.1. HIGH COST OF TESTING AND TREATMENT
3.2.2. INFERTILITY CONSIDERED A SOCIAL TABOO
3.2.3. POSSIBLE RISKS ASSOCIATED WITH INFERTILITY TREATMENTS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON INFERTILITY TESTING & TREATMENT MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
4.6. KEY BUYING CRITERIA
4.6.1. TREATMENT OPTIONS
4.6.2. QUALITY OF MEDICAL PROCEDURES
4.6.3. PRICE OF TREATMENTS
4.6.4. SHIFT TOWARDS MEDICAL TOURISM
4.6.5. REIMBURSEMENT
4.7. VALUE CHAIN ANALYSIS
4.7.1. RAW MATERIAL PROCUREMENT
4.7.2. MANUFACTURING
4.7.3. SUPPLY LOGISTICS
4.7.4. DISTRIBUTION CHANNELS
4.7.5. END-USERS
5. MARKET BY GENDER
5.1. MALE
5.1.1. MALE INFERTILITY TESTING
5.1.1.1. DNA FRAGMENTATION
5.1.1.2. OXIDATIVE STRESS ANALYSIS
5.1.1.3. SPERM PENETRATION ASSAY
5.1.1.4. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
5.1.1.5. SPERM AGGLUTINATION
5.1.1.6. MICROSCOPIC EXAMINATION
5.1.1.7. OTHERS
5.1.2. MALE INFERTILITY TREATMENT
5.1.2.1. MEDICATION
5.1.2.2. ASSISTED REPRODUCTIVE TECHNOLOGY & VARICOCELE SURGERY
5.2. FEMALE
5.2.1. FEMALE INFERTILITY TESTING
5.2.1.1. OVULATION TESTING
5.2.1.2. HYSTEROSALPINGOGRAPHY
5.2.1.3. LAPAROSCOPY
5.2.1.4. TRANSVAGINAL ULTRASOUND
5.2.1.5. OVARIAN RESERVE TESTING
5.2.1.6. HORMONAL LEVEL TESTING
5.2.1.7. OTHERS
5.2.2. FEMALE INFERTILITY TREATMENT
5.2.2.1. IVF WITH ICSI
5.2.2.2. IUI
5.2.2.3. IVF WITHOUT ICSI
5.2.2.4. SURROGACY
5.2.2.5. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. KEY GROWTH ENABLERS
7.1.2. KEY CHALLENGES
7.1.3. KEY PLAYERS
7.1.4. COUNTRY ANALYSIS
7.1.4.1. UNITED KINGDOM
7.1.4.2. GERMANY
7.1.4.3. FRANCE
7.1.4.4. ITALY
7.1.4.5. RUSSIA
7.1.4.6. BELGIUM
7.1.4.7. POLAND
7.1.4.8. REST OF EUROPE
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS & AGREEMENTS
8.2. COMPANY PROFILES
8.2.1. ADORFEM
8.2.2. BANGKOK IVF CENTER
8.2.3. COOK MEDICAL INC
8.2.4. COOPER SURGICAL
8.2.5. CREATE FERTILITY CENTRE
8.2.6. EMD GROUP (MERCK KGAA)
8.2.7. ENDO INTERNATIONAL PLC
8.2.8. ESCO MEDICAL
8.2.9. FERRING PHARMACEUTICALS
8.2.10. FERTILITY FIRST
8.2.11. FUJIFILM IRVINE SCIENTIFIC
8.2.12. GENEA LTD
8.2.13. HALOTECH DNA
8.2.14. HAMILTON THRONE LTD
8.2.15. IVFTECH
8.2.16. LABOTECT GMBH
8.2.17. OLYMPUS CORPORATION
8.2.18. PROGYNY
8.2.19. THERMO FISHER SCIENTIFIC INC
8.2.20. VITROLIFE AB
1. ADORFEM
2. BANGKOK IVF CENTER
3. COOK MEDICAL INC
4. COOPER SURGICAL
5. CREATE FERTILITY CENTRE
6. EMD GROUP (MERCK KGAA)
7. ENDO INTERNATIONAL PLC
8. ESCO MEDICAL
9. FERRING PHARMACEUTICALS
10. FERTILITY FIRST
11. FUJIFILM IRVINE SCIENTIFIC
12. GENEA LTD
13. HALOTECH DNA
14. HAMILTON THRONE LTD
15. IVFTECH
16. LABOTECT GMBH
17. OLYMPUS CORPORATION
18. PROGYNY
19. THERMO FISHER SCIENTIFIC INC
20. VITROLIFE AB
